Replimune Group, Inc. (REPL) income statement
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.81+0.12 (+0.61%)
Close on Nov 18, 2026Market cap $1.88BP/E –Yield –
Replimune Group, Inc. financial ratios
See a number that looks wrong?